{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:44:45Z","timestamp":1745210685496},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previous studies investigated the frequency of different adverse events of COVID-19 vaccines. However, this study compares these adverse events between the two main COVID-19 vaccines used in Saudi Arabia (Pfizer-BioNTech and Oxford-AstraZeneca) using telemedicine technology. A cross-sectional study was conducted among 958 individuals, 7\u00a0days after receiving either Pfizer-BioNTech or Oxford-AstraZeneca vaccines during June 2021. Immediate adverse events were reported by 1.04% and 2.09% for Pfizer-BioNTech and Oxford-AstraZeneca vaccines, respectively, with no serious events. Recipients of Pfizer-BioNTech vaccine had a higher percentage of local adverse events (24.8% versus 9.8% in AstraZeneca vaccine). The most common reported systemic adverse events in both vaccines respectively were general fatigue (23.1% and 25.1%), fever (18.5% and 27.2%), myalgia (20.6% and 20.3%), and headache (15.2% and 17.2%). No significant difference was recorded between both vaccines regarding overall systemic adverse events; however, they were more frequent following the first dose of AstraZeneca vaccine compared to Pfizer-BioNTech vaccine, while the reverse was observed for the second dose. Adverse events were more frequent in females and younger age groups for both vaccines. Most of systemic and local adverse events were mild in nature. Further cohort studies are recommended to investigate the long-term adverse events of COVID-19 vaccines.<\/jats:p>","DOI":"10.1038\/s41598-022-23471-8","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T11:07:00Z","timestamp":1668510420000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse events following administration of COVID-19 vaccines in Saudi Arabia"],"prefix":"10.1038","volume":"12","author":[{"given":"Saleh","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Jokhdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaffar A.","family":"Al-Tawfiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Al-Otaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Almudarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Alabdulkareem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alhan","family":"Haji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"23471_CR1","unstructured":"European Centre for Disease Prevention and Control, Timeline of ECDC\u2019s response to COVID-19. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/timeline-ecdc-response (2020) (Accessed 25 Feb 2021)."},{"key":"23471_CR2","unstructured":"World Health Organization, Covid-19 Vaccines. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines, (2021) (Accessed 20 Jan 2021)."},{"issue":"27","key":"23471_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. Thomas, S. J & Kitchin, N. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383(27), 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23471_CR4","unstructured":"World Health Organization, The Oxford\/AstraZeneca COVID-19 vaccine: what you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know (2021) (Accessed 12 Sept 2021)."},{"key":"23471_CR5","unstructured":"Food and Drug Administration, Development and licensure of vaccines to prevent COVID-19: guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/searchfda-guidance-documents\/development-and-licensurevaccines-prevent-covid-19 (2020) (Accessed 19 Jan 2021)."},{"key":"23471_CR6","doi-asserted-by":"publisher","first-page":"102119","DOI":"10.1016\/j.tmaid.2021.102119","volume":"43","author":"A Assiri","year":"2021","unstructured":"Assiri, A. et al. Launching COVID-19 vaccination in Saudi Arabia: Lessons learned, and the way forward. Travel Med. Infect. Dis. 43, 102119 (2021).","journal-title":"Travel Med. Infect. Dis."},{"key":"23471_CR7","unstructured":"Centers for Diseases Control and Prevention (CDC). Reactions and adverse events of the Pfizer-BioNTech COVID-19 vaccine (2021)."},{"key":"23471_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572\u2013577 (2021).","journal-title":"Nature"},{"key":"23471_CR9","unstructured":"World Health Organization, WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (2020) (Accessed 26 Sept 2021)."},{"issue":"(Suppl 6)","key":"23471_CR10","doi-asserted-by":"publisher","first-page":"e2021487","DOI":"10.23750\/abm.v92iS6.12365","volume":"92","author":"V Gianfredi","year":"2021","unstructured":"Gianfredi, V. Minerva, M. & Casu, G. et al. Immediate adverse events following COVID-19 immunization. A cross-sectional study of 314,664 Italian subjects. Acta Bio Medica Atenei Parmensis 92(Suppl 6), e2021487. https:\/\/doi.org\/10.23750\/abm.v92iS6.12365 (2021).","journal-title":"Acta Bio Medica Atenei Parmensis"},{"key":"23471_CR11","unstructured":"AARP, Health Conditions and Treatments, What Are the Side Effects of COVID-19 Vaccines?. https:\/\/www.aarp.org\/health\/conditions-treatments\/info-2020\/coronavirus-vaccine-side-effects\/ (2020) (Accessed 17 Jan 2021)."},{"key":"23471_CR12","unstructured":"Centers for disease control and prevention, Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/pfizer\/reactogenicity.html, (2020) (Accessed 13 Dec 2020)."},{"key":"23471_CR13","unstructured":"NHS, Coronavirus (COVID-19) vaccines. https:\/\/www.nhs.uk\/conditions\/coronavirus-covid-19\/coronavirus-vaccination\/coronavirus-vaccine\/ (Accessed 18 Sept 2021)."},{"issue":"10283","key":"23471_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0140-6736(21)00762-5","volume":"397","author":"SD \u00d8stergaard","year":"2021","unstructured":"\u00d8stergaard, S. D., Schmidt, M., Horv\u00e1th-Puh\u00f3, E., Thomsen, R. W. & S\u00f8rensen, H. T. Thromboembolism and the Oxford\u2013AstraZeneca COVID-19 vaccine: Side-effect or coincidence?. Lancet 397(10283), 1441\u20131443 (2021).","journal-title":"Lancet"},{"issue":"14","key":"23471_CR15","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.3390\/ijerph19148287","volume":"19","author":"NS Alghamdi","year":"2022","unstructured":"Alghamdi, N. S. & Alghamdi, S. M. The role of digital technology in curbing COVID-19. Int. J. Environ. Res. Public Health. 19(14), 8287. https:\/\/doi.org\/10.3390\/ijerph19148287 (2022).","journal-title":"Int. J. Environ. Res. Public Health."},{"issue":"9","key":"23471_CR16","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.2196\/19338","volume":"22","author":"M Hassounah","year":"2020","unstructured":"Hassounah, M., Raheel, H. & Alhefzi, M. Digital response during the COVID-19 pandemic in Saudi Arabia. J. Med. Internet Res. 22(9), e19338. https:\/\/doi.org\/10.2196\/19338 (2020).","journal-title":"J. Med. Internet Res."},{"key":"23471_CR17","doi-asserted-by":"crossref","unstructured":"Alghamdi, S. M., Alsulayyim, A. S., Alqahtani, J. S., Aldhahir, A. M. Digital health platforms in Saudi Arabia: determinants from the COVID-19 pandemic experience. In Healthcare Vol. 9, No. 11, 1517 (2021).","DOI":"10.3390\/healthcare9111517"},{"key":"23471_CR18","unstructured":"Saudi Ministry of Health Portal. MOH Minister to Launch the 937-Service (MOH Emergency Call Center) Tomorrow. https:\/\/www.moh.gov.sa\/en\/937\/Pages\/default.aspx (2013)."},{"key":"23471_CR19","unstructured":"FDA, FDA Briefing Document. Pfizer-BioNTech COVID-19 vaccine. https:\/\/www.fda.gov\/media\/144245\/download, (2020) (Accessed 17 Jan 2021)."},{"issue":"1","key":"23471_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-021-00878-5","volume":"10","author":"M Chen","year":"2021","unstructured":"Chen, M. et al. Safety of SARS-CoV-2 vaccines: A systematic review and meta-analysis of randomized controlled trials. Infect. Dis. Poverty 10(1), 1\u201312 (2021).","journal-title":"Infect. Dis. Poverty"},{"key":"23471_CR21","unstructured":"Food and Drug Administration, Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccineexternalicon, (2021) (Accessed 12 Jan 2021)."},{"issue":"8","key":"23471_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/biology10080752","volume":"10","author":"M Klugar","year":"2021","unstructured":"Klugar, M. et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology 10(8), 752 (2021).","journal-title":"Biology"},{"issue":"3","key":"23471_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/life11030249","volume":"11","author":"AG Mathioudakis","year":"2021","unstructured":"Mathioudakis, A. G. et al. Self-reported real-world safety and reactogenicity of covid-19 vaccines: A vaccine recipient survey. Life 11(3), 249 (2021).","journal-title":"Life"},{"issue":"6","key":"23471_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/vaccines9060577","volume":"9","author":"O Abu-Hammad","year":"2021","unstructured":"Abu-Hammad, O. et al. Side effects reported by Jordanian healthcare workers who received COVID-19 vaccines. Vaccines 9(6), 577 (2021).","journal-title":"Vaccines"},{"key":"23471_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijid.2021.07.052","volume":"110","author":"S Al Bahrani","year":"2021","unstructured":"Al Bahrani, S. et al. Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia. Int. J. Infect. Dis. 110, 359\u2013362 (2021).","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"23471_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/vaccines9060674","volume":"9","author":"A Alhazmi","year":"2021","unstructured":"Alhazmi, A. et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines 9(6), 674 (2021).","journal-title":"Vaccines"},{"issue":"6","key":"23471_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/vaccines9060556","volume":"9","author":"MMM Hatmal","year":"2021","unstructured":"Hatmal, M. M. M. et al. Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines 9(6), 556 (2021).","journal-title":"Vaccines"},{"key":"23471_CR28","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/IJGM.S310497","volume":"14","author":"NA El-Shitany","year":"2021","unstructured":"El-Shitany, N. A. et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int. J. Gen. Med. 14, 1389 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"23471_CR29","unstructured":"Medicines & Healthcare Products Regulatory Agency. Coronavirus vaccine-weekly summary of Yellow Card reporting (Medicines & Healthcare Products Regulatory Agency, 2021)."},{"key":"23471_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect. Dis. 21, 939\u2013949 (2021).","journal-title":"Lancet Infect. Dis."},{"issue":"7830","key":"23471_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586(7830), 589\u2013593 (2020).","journal-title":"Nature"},{"issue":"7","key":"23471_CR32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/jcm10071428","volume":"10","author":"A Riad","year":"2021","unstructured":"Riad, A. et al. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J. Clin. Med. 10(7), 1428 (2021).","journal-title":"J. Clin. Med."},{"key":"23471_CR33","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.pmedr.2021.101595","volume":"24","author":"AM Almohaya","year":"2021","unstructured":"Almohaya, A. M. et al. Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia. Prev. Med. Rep. 24, 101595 (2021).","journal-title":"Prev. Med. Rep."},{"issue":"3","key":"23471_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.iac.2014.04.004","volume":"34","author":"JC Caubet","year":"2014","unstructured":"Caubet, J. C. & Ponvert, C. Vaccine allergy. Immunol. Allergy Clin. North Am. 34(3), 597\u2013613 (2014).","journal-title":"Immunol. Allergy Clin. North Am."},{"issue":"1","key":"23471_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9, C., Laup\u00e8ze, B., Del Giudice, G., Didierlaurent, A. M. & Da Silva, F. T. The how\u2019s and what\u2019s of vaccine reactogenicity. npj Vaccines 4(1), 1\u201311 (2019).","journal-title":"npj Vaccines"},{"issue":"10267","key":"23471_CR36","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396(10267), 1979\u20131993 (2020).","journal-title":"Lancet"},{"issue":"10269","key":"23471_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269), 99\u2013111 (2021).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23471-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23471-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23471-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T17:07:23Z","timestamp":1668532043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23471-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23471"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23471-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19551"}}